PetMed Express, Inc.

What they do

The company sells directly to consumers through Petmeds.com, PetCareRx.com, customer contact centers and iOS/Android apps, connecting each order to the customer's licensed veterinarian for prescription approval. It operates two pharmacy locations, employs licensed pharmacists, and holds NABP and LegitScript accreditation, with a 50-state licensed Pharmacist-in-Charge at each site. Merchandise spans branded and generic pharmaceuticals, compounded prescriptions, OTC health and wellness products, Rx and non-Rx food, treats and supplies, plus AutoShip recurring delivery and educational content on pethealthmd.com. It also offers employee benefits programs through partner Pet Synergy Group's PetAssure.

Revenue drivers

• Prescription medications (Rx and generic) — Core legacy category of branded and generic pet pharmaceuticals dispensed against veterinarian authorization; the earnings release attributes the year-over-year sales decline primarily to lower prescription medication sales and lower consumer promotional usage.
• OTC health, wellness, supplements and food — Over-the-counter solutions, vitamins and supplements, Rx and non-Rx food, treats and pet supplies; the PetCareRx acquisition expanded this catalog beyond the core prescription offering, though the excerpts give no separate revenue split.
• AutoShip and recurring fulfillment — Personalized AutoShip capability and pharmacy fulfillment support repeat ordering; no standalone revenue figure is disclosed in the excerpts.
• Manufacturer rebates and freight economics — Gross profit is sensitive to manufacturer rebates as a percentage of sales and net freight cost per order; the latest quarter's lower gross profit was driven by lower rebates as a percentage of sales, partly offset by lower net freight per order.

Recent performance

Fiscal 2026 (year ended March 31, 2026) revenue was $179.0M with a net loss of $57.3M and diluted EPS of $(2.74), versus revenue of $227.0M and a net loss of $6.3M in fiscal 2025. For the first quarter ended June 30, 2026, net sales were $41.0M, down 19.9% from $51.2M a year earlier, with the decline attributed to lower consumer promotional usage more than offset by lower prescription medication sales. Q1 net loss was $6.1M, or $(0.28) per diluted share, versus a $34.2M loss, or $(1.65) per share, a year earlier, mainly due to the absence of prior-year goodwill and trade name impairments plus lower G&A and advertising. Adjusted EBITDA was $(3.4)M versus $(2.7)M in the prior-year period. Quarterly revenue has been roughly flat at $44.4M, $40.7M, $42.8M and $41.0M across the last four reported quarters. Fiscal 2026 operating cash flow was $(28.4)M and no dividends were paid in fiscal 2025 or 2026.

Strategy

Management describes its aim as establishing a direct, clear path back to sustainable profitability, and points to sequential quarterly net sales stabilization. Marketing spend is being made more efficient: 70,000 new customers acquired in the June 2026 quarter with cost of acquiring a new customer down 15% year-over-year, alongside a nearly 14% reduction in general and administrative expenses. The company completed an enterprise-wide rollout of a new SAP ERP system during the quarter. It also announced a sale-leaseback transaction, which management frames as strengthening the balance sheet and enhancing financial flexibility to invest in higher-potential initiatives.

Risks

• Regulatory and pharmacy licensing — Failure to comply with state and federal rules on dispensing prescription pet medications could lead to reprimands, sanctions, fines, suspensions or loss of pharmacy licenses; the Florida home-state license runs to February 28, 2027 and the PetCareRx New York license to April 30, 2028, with no guarantee of renewal.
• Revenue and margin erosion — Fiscal 2026 revenue fell to $179.0M from $227.0M and the June 2026 quarter fell 19.9% year-over-year, with gross profit pressured by lower manufacturer rebates as a percentage of sales.
• Continued losses and cash use — Fiscal 2026 produced a $57.3M net loss and $(28.4)M of operating cash flow, and the June 2026 quarter added a $6.1M net loss with $(3.4)M adjusted EBITDA.
• Balance sheet and liquidity — At June 30, 2026, total liabilities were $40.8M against $23.0M of shareholder equity and $13.1M of cash and equivalents.

Outlook

The company characterizes the June 2026 quarter as showing continued progress toward sustainable profitability and notes that net sales have stabilized sequentially over the past several quarters. Management highlights efficient marketing (70,000 new customers, customer acquisition cost down 15%), a nearly 14% reduction in G&A, completion of the SAP ERP rollout, and the sale-leaseback as steps to strengthen the balance sheet and fund initiatives expected to drive shareholder returns. No numeric revenue or earnings guidance is provided in the excerpts. The earnings release directs readers to risk factors in the Form 10-K for the year ended March 31, 2026.